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Tony Hunter dimerization. Point mutations in the Neu/ErbB2 trans-
membrane domain and in the extracellular domain ofMolecular Biology and Virology Laboratory
the CSF-1 receptor result in dimerization. The Npm-The Salk Institute
Alk fusion protein, generated by the t(2;5) chromosomal10010 North Torrey Pines Road
translocation in anaplastic large cell lymphoma, oligo-La Jolla, California 92037–1099
merizes and is activated by virtue of its N-terminal
nucleophosmin (Npm) sequences, which are fused to
the entire cytoplasmic domain of Alk, a receptor-likeThe increasing complexity of growth control pathways
PTK (Morris et al., 1994; Fujimoto et al., 1996). The Tel-has beenparalleled by the increasingly diverse functions
PDGFb receptor fusion, generated by the t(5;12) translo-uncovered for oncoproteins and tumor suppressor pro-
cation in chronic myelomonocytic leukemia, joins theteins. Our awareness of the interconnections between
N-terminal part of Tel, an Ets family transcription factor,growth factor- and growth inhibitor-initiated signaling
with the entire cytoplasmic domain of the PDGFbR PTKpathways has furthered our understanding of mecha-
gene, resulting in dimerization through a helix-loop-helix
nisms underlying malignant transformation, but at the
motif in the Tel domain and constitutive PTK activation
same time has indicated how complex cell growth con-
(Golub et al., 1994).
trol networks will be. In the past few years, there has
Tel proves to be a common fusion partner in leukemia-
been enormous progress in elucidating the details of associated chromosomal translocations. In acute my-
mitogenic signaling. The positioning of multiple onco- eloid leukemias carrying the t(12;9) translocation, most
proteins and tumor suppressor proteins on the same of Tel, including the helix-loop-helix motif, is fused to
pathway has underscored the importance of some of the Abl nonreceptor PTK upstream of the SH3 domain,
these signaling pathways in transformation. For in- resulting in a dimeric protein that is constitutively tyro-
stance, ErbB, Ras, and Raf all lie on the ERK MAP kinase sine phosphorylated, and localizes to the cytoskeleton
(MAPK) pathway, which through phosphorylation of (Golub et al., 1996). This activation mechanism is similar
members of the Ets protein family leads to induction of to that for Bcr-Abl, the product of the t(9;21) chromo-
immediate early genes like c-fos. some fusion found in chronic myelogenous leukemia,
The functions of oncoproteins and tumor suppressor where the N-terminal Bcr domain provides a coiled–coil
proteins have been more than adequately reviewed in type oligomerization domain. However, oncogenic acti-
several places in the past few years. Taking this into vation of othernonreceptor PTKsdoes not involve fusion
account, and given the space constraints, I have chosen with dimerization partners but rather loss of a negative
to discuss examples of more recently discovered onco- regulatory function, as is the case for v-Src, where the
proteins and tumor suppressor proteins that illustrate C-terminal regulatory tyrosine of c-Src is deleted.
new principles of cell regulation, emphasizing how such Another receptor PTK, Ret, had been found to be
oncogenically activated in multiple ways. Ret was origi-principles allow us to establish a regulatory network.
nally discovered as an oncoprotein in a transfectionThe repertoire of cell surface receptor types involved in
assay as an artifactual fusion of the cytoplasmic domainoncogenesis has grown, and I begin with an overview
with a fragment of the Rfp zinc finger protein resultingof several types of receptor-driven pathways implicated
in a dimeric constitutively active form of Ret. Ret hasin oncogenesis. I then trace oncoprotein-activated sig-
subsequently been shown, however, to be mutated innaling pathways to the nucleus and discuss the intrigu-
specific human tumors including thyroid papillary carci-ing connections between the actin cytoskeleton and
nomas. A number of Ret-derived oncoproteins havetransformation. I end by reviewing the role that onco-
been characterized, and in every case the cytoplasmicproteins play in triggering cell cycle progression and
domain is fused to an N-terminal domain that affordspreventing apoptosis.
constitutive dimerization and activation (e.g. the RIa
PKA regulatory subunit). Ret is also of interest because
Receptor Pathways to Oncogenesis mutant forms have been identified as thecause of hered-
Receptor Protein-Tyrosine Kinases itary cancers known as multiple endocrine neoplasia
The role of mutant activated receptor protein-tyrosine (MEN) type 2A and 2B and familial medullary thyroid
kinases (PTKs) in oncogenesis is well established. An carcinoma (FMTC) (van Heyningen, 1994). In MEN2A,
important principle in the activation of receptor PTKs is a variety of mutations in the Ret extracellular do-
ligand-mediated dimerization. Increasing evidence indi- main commonly involving Cys have been found (e.g.
cates that oncogenic activation of receptor PTKsoccurs Cys634Arg). Such mutations lead to constitutive activa-
through mutations that lead to constitutive dimerization tion, presumably through dimerization mediated by di-
and activation of the cytoplasmic catalytic domain. This sulfide bonding of unpaired Cys. In MEN2B, the mutation
process has been particularly well established in the is in the catalytic domain (Met918Thr), and this not only
case of Tpr-Met, where the N-terminal Tpr domain con- activates Ret but also alters its substrate specificity,
tains a leucine zipper that is essential for dimerization making it more similar to that of the Src family PTKs.
of the attached Met/HGF receptor domain, which leads A novel but indirect mechanism of receptor PTK acti-
to constitutive activation and oncogenic transformation vation is emerging from the study of v-Cbl, the oncopro-
(Rodrigues and Park, 1993). There are many other exam- tein encoded by the Cas NS-1 murine leukemia retrovi-
rus, which was derived from c-Cbl through C-terminalples of mutations that cause constitutive receptor PTK
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truncation. c-Cbl is a cytoplasmic protein that is tyrosine been identified as Wnt receptors (Bhanot et al., 1996;
Yang-Snyder et al., 1996). Frizzled is a Drosophila polar-phosphorylated in response toEGF and other cytokines,
and associates with the EGF receptor via its N-terminal ity gene product required for the development of normal
tissue polarity in the epidermis. Frizzled family membersdomain (Galisteo et al., 1995). c-Cbl is homologous to
the C. elegans protein Sli1, which was identified as a have seven transmembrane domains and a cysteine-
rich extracellular domain required for Wingless binding.negative regulator of signaling from the EGF receptor-
related Let23 receptor PTK in vulval development (Yoon The membrane topology of Frizzled family members is
similar to that of G protein-coupled receptors, sug-et al., 1995). c-Cbl mayplay a similar role indownregulat-
ing receptor PTK signaling in mammalian systems. v-Cbl gesting that they might be coupled to G proteins, but
there is no direct evidence that this is the case.could then act as a dominant negative inhibitor of c-Cbl
function by blocking its interaction with receptor PTKs, Although the signaling pathway downstream of Wnt
is not fully understood, several components of this path-thus upregulating mitogenic signaling.
Secreted factors that signal through receptor PTKs way are implicated in cancer (Figure 1). Genetic analysis
in Drosophila, and the effects of ectopic expression ofare also implicated in oncogenesis. At least four of the
large family of FGF genes have been identified as onco- proteins on Xenopus development have defined a path-
way from Wnt leading to Dishevelled, Shaggy/Zeste-genes in human tumors. Moreover, although germ line
mutations that constitutively activate FGFR1, -2, and white 3 (GSK3), and Armadillo (b-catenin) (Orsulic and
Peifer, 1996; Perrimon, 1996). Dishevelled is a cyto--3 result in developmental abnormalities of the skeletal
system rather than hereditary cancers, FGFR2 is com- plasmic protein with little homology to other proteins,
except that it has a PDZ domain; it is phosphorylatedmonly amplified in poorly differentiated gastric carcino-
mas (Hattori et al., 1992), implying that ectopic expres- in response to Wingless and associates with mem-
branes. Intriguingly, Frizzled family proteins have thesion of FGFs and inappropriate activation of FGF
receptor PTKs can result in tumorigenesis. SXV C-terminal consensus sequence required for PDZ
domain binding, and Dishevelled may interact directlySecreted factors also play important roles in tumor
metastasis and angiogenesis. For instance, hepatocyte with Frizzled at the membrane.
Shaggy/Zeste-white 3 is a functional homolog of thegrowth factor (HGF)/scatter factor may play a role in
metastasis, since it increases the motility and invasive- mammalian glycogen synthase kinase 3 (GSK3) protein
kinase. GSK3 normally suppresses the Wnt signalingness of epithelial and endothelial cells. The HGF recep-
tor gene (MET) is amplified and overexpressed in a num- pathway, and recent biochemical analysis indicates that
Wingless decreases GSK3 activity (Cook et al., 1996).ber of tumor types, and in some cases the HGF receptor
is constitutively activated (Di Renzo et al., 1995). At least Activated Dishevelled itself could be a GSK3 inhibitor.
The GSK3 substrates whose dephosphorylation propa-three families of growth factor receptor PTKs are in-
volved in angiogenesis, namely the vascular endothelial gates the Wingless signal have not yet been identified,
but GSK3 is a cytoplasmic protein, and likely targetscell growth factor (VEGF) and FGF receptor families,
and the Tie family. Many solid tumors produce VEGF, are Armadillo or a protein that interacts with Armadillo,
such as the adenomatous polyposis coli gene productespecially in response to hypoxia, a condition that com-
monly exists in solid tumors. Coinoculation of fibroblasts (APC), which is mutated in most colon cancers (Kinzler
and Vogelstein, 1996). Armadillo is a homolog of b-cate-producing a retrovirus expressing a truncated “domi-
nant-negative” form of Flk1, one of the VEGF receptors, nin; the catenins are a family of proteins that associate
with the cytoplasmic domains of cadherins, which arewith a variety of tumor cell types significantly inhibits
tumor growth and angiogenesis in nude mice (Millauer cell-cell interaction receptors that form part of the ad-
herens junction. APC associates with a- and b-catenins,et al., 1994). This supports a critical role for VEGF in
tumor angiogenesis. IGF2 also proves to be critical for and by triggering degradation of free b-catenin this inter-
action appears to be critical for maintaining a low leveloncogene-induced tumors in vivo (Christofori et al.,
1994). of free b-catenin. GSK3 phosphorylates APC, increasing
b-catenin binding (Rubinfeld et al., 1996). Thus, GSK3The Wnt/Wingless Pathway
Another secreted factor that plays a role in tumorigene- activity could be required for b-catenin degradation.
b-catenin itself is also a likely target for GSK3, sincesis is Wnt1. wnt1 was one of the first examples of an
oncogene activated by provirus insertion, having been wild-type GSK3 phosphorylates b-catenin at a con-
served site whose mutation increases its stability (Yostdiscovered as a common site of integration in MMTV-
induced mouse mammary carcinomas. Wnt1 was sub- et al., 1996). The net effect of loss of APC or inactivation
of GSK3 will be to increase the free pool of b-catenin.sequently shown to be a member of a family of secreted
proteins that are important for early development; this Free b-catenin can signal by virtue of its association
with members of TCF/LEF family of HMG box transcrip-family includes the Drosophila Wingless protein, which
plays multiple roles in Drosophila development by influ- tion factors, an interaction that allows a LEF-1/b-catenin
complex to accumulate in the nucleus and drive tran-encing cell fate decisions. Although Wnt1 expression is
restricted to the nervous system in vertebrates, being scription (Behrens et al., 1996; Molenaar et al., 1996).
Consistent with a signaling function for b-catenin in therequired for the development of the midbrain and cere-
bellum, other family members areexpressed in the mam- Wnt pathway, Wingless causes accumulation of cyto-
plasmic Armadillo in Drosophila, and Wnt1 expressionmary gland. Despite a large body of information about
Wnt function, mechanistic insight into how Wnt1 trans- in CM57G mouse mammary cells leads to upregulation
of b- and g-catenins, due to the stabilization of the solu-forms has been been slow to emerge. In part this was
because the Wnt receptor remained elusive. Very re- ble pools, which normally turn over extremely rapidly
(Papkoff et al., 1996). In this manner, Wnts can inducecently, however, proteins in the Frizzled family have
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Figure 1. Developmental Signaling Pathways
Involved in Cancer
Proteins that have been implicated as onco-
proteins or tumor suppressor proteins are in
white letters on black fill.
expression of target genes; genes induced by Wingless implicated in cancer. Patched is a transmembrane pro-
tein that acts in opposition to the secreted Hedgehoginclude those for the transcriptional repressor Engrailed,
theTGFb family member Decapentaplegic, and the cyto- protein in controlling cell fates and growth in many
tissues (Nusse, 1996). Vertebrate homologs of Sonickine Hedgehog. Autocrine expression of Wnts could
then lead to expression of genes that block cellular dif- hedgehog, Smoothened, and Patched have been identi-
fied, and recent evidence indicates that Patched is aferentiation, and contribute to the malignant phenotype.
Cadherins and Catenins receptor for Sonic hedgehog (Marigo et al., 1996; Stone
et al., 1996). Smoothened, a serpentine receptor-likeCadherins are surface receptors that mediate specific
cell-cell interactions through homotypic association, protein distantly related to Frizzled, is negatively regu-
lated in a tonic fashion by Patched, possibly throughand also provide a means of cell-cell signaling. There
are several potential connections between cadherin ad- direct interaction (Stone et al., 1996), and this inhibition
is relieved upon binding of Hedgehog (Figure 1). Acti-hesion and carcinogenesis. Intracellular signaling via
cadherins involves activation of Src family PTKs, which vated Smoothened downregulates cAMP-dependent
protein kinase (PKA), presumably through decreasingleads to tyrosine phosphorylation of catenins. Cadherin-
mediated signaling may act to regulate the availability cAMP levels. In principle, this could occur through nega-
tive regulation of adenylyl cyclase by a Gi family proteinof free b-catenin (Fagotto et al., 1996), and therefore
feed into the same signaling pathway as the Wnt recep- activated by a G protein-coupled receptor such as
Smoothened, but this effect is more likely to be indirecttor. b-catenin is a v-Src PTK substrate and its phosphor-
ylation perturbs cadherin function in v-Src-transformed and involve the Fused protein kinase (Therond et al.,
1996). The net effect is to activate the Cubitus inter-cells decreasing cell-cell adhesion (Matsuyoshi et al.,
1992). p120 is a catenin-related protein, which binds ruptus zinc finger transcription factor resulting in induc-
tion of target genes such as wingless. Wingless activa-to cadherins but not APC, and is phosphorylated on
tyrosine in response to the activation of the EGF, PDGF, tion of Frizzled in a neighboring cell leads to increased
Hedgehog production, which acts back on the Wing-and CSF-1 receptors and in v-Src-transformed cells
(Reynolds et al., 1994). A truncated b-catenin, which is less-producing cell to induce further Wingless expres-
sion. Smoothened might also act as an autocrine recep-detected in certain human cancer cell lines, disrupts
the interaction between E-cadherin and a-catenin, and tor for Wingless; this would activate the Smoothened
signaling pathway, leading to increased Wingless ex-causes loss of intercellular adhesiveness, implying that
mutation of b-catenin can play a role in cancer (Oyama pression. In combination, these Hedgehog/Wingless
feedback loops act to reinforce the mutually distinctet al., 1994). In addition, the expression of E-cadherin
is often downregulated in cancer cells, and mutations fates of cells at a compartment boundary.
Mutations of the human homolog of the Patched genein E-cadherin have been observed in tumors. It is possi-
ble that mutations of b-catenin and E-cadherin not only are responsible for the hereditary nevoid basal cell carci-
noma syndrome, which is an autosomal dominant disor-decrease tumor cell adhesion, but also upregulate the
Wnt signaling pathway. der characterized by multiple basal cell carcinomas and
a variety of other tumors and developmental abnormali-The Hedgehog/Patched Pathway
The Hedgehog/Patched/Smoothened system, which is ties, mapping to chromosome 9q22.3. Familial and spo-
radic nevoid basal cell carcinomas display loss of heter-intimately connected with the Wingless/Frizzled system
in determining cell fate decisions in Drosophila, is also ozygosity in this region, consistent with the Patched
Cell
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gene being a tumor suppressor gene (Gailani et al., 1996; Truncationof theNotch extracellular domain activates
Notch signaling constitutively in Drosophila and verte-Hahn et al., 1996a; Johnson et al., 1996c). Assuming
that in vertebrates Patched signaling is required for cell brates. All the putative Notch-derived oncoproteins
have deletions in the extracellular domain consistentfate decisions and differentiation, as it is in Drosophila,
then loss of Patched would lead to constitutive activa- with their being constitutively activated. Tan1 (Notch1)
was initially identified as the product of a chromosomaltion of Smoothened, causing inappropriate growth of
basal layer cells, ultimately resulting in carcinogenesis. translocation, t(7;9), in a T lymphoblastic leukemia (Elli-
sen et al., 1991). Tan1 induces T cell leukemias whenIn principle, an activating mutation in Smoothened that
blocks its interaction with Patched could also play a bone marrow cells infected with a retrovirus expressing
Tan1 are reintroduced into mice, establishing its creden-role in carcinogenesis. Intriguingly, the GLI1gene, which
encodes a zinc finger transcription factor related to Cu- tials as an oncoprotein (Pear et al., 1996). Full-length
and, less commonly, truncated Notch1 is frequentlybitus interruptus, is amplified in a subset of human tu-
mors (Kinzler and Vogelstein, 1990); this could have the overexpressed in thymomas arising in MMTV-c-Myc
transgenic mice, suggesting that the Notch pathwayssame consequence as abrogating negative regulation
of Smoothened by Patched. can collaborate with c-Myc in oncogenesis (Girard et
al., 1996). Int3 (Notch4) was identified as a commonThe Notch Pathway
At least three members of the growing Notch/Lin12 integration site for the MMTV provirus in MMTV-induced
mammary carcinomas, resulting in production of anfamily of receptors (currently four in mammals), Tan1
(Notch1), Notch2, and Int3 (Notch4), are associated with N-terminally truncated protein. Expression of Int3 from
a transgene induces mammary carcinomas (Jhappan etcancer. Notch was initially described in Drosophila,
where it acts as a suppressor of cellular differentiation al., 1992). A third Notch family member, Notch2, has
been implicated in tumorigenesis through the isolationwhen activated by interaction with one of its ligands on
an adjacent cell, such as Delta or Serrate. A great deal of recombinant feline leukemia virus genomes from vi-
rally induced thymic lymphomas that encode an N-ter-has been learned about the Notch/Lin12 signaling path-
way from genetic analysis in Drosophila and C. elegans. minally truncated form of Notch2 that is targeted to the
nucleus (Rohn et al., 1996). In every case, it seems likelyThe cytoplasmic juxtamembrane domain of Notch inter-
acts with Suppressor of hairless [Su(H)], which is a tran- that the truncated Notch protein is signaling constitu-
tively, thus blocking differentiation and causing continu-scriptional repressor that acts together with Hairless
(Honjo, 1996). When Notch is activated by a ligand, Su(H) ous proliferation.
Another intriguing connection between the Notch sig-is released and migrates to thenucleus, where it induces
expression of Hairy and Enhancer of split, which are naling pathway and transformation comes from studies
on Epstein Barr virus. EBNA2, an EBV-encoded proteinbHLH transcriptional repressors that block neural differ-
entiation. There is still a debate about how Su(H) is needed for transformation of B cells, is an activator of
latent viral and cellular genes. However, EBNA2 doesreleased, with one attractive model proposing that the
cytoplasmic domain of Notch is cleaved and then trans- not interact directly with EBNA2-responsive sequences
in its target genes. Instead, it has been found to interactlocates to the nucleus with Su(H). The bound Notch
would then mask the Su(H) repression domain and con- with CBF1 and drive transactivation of genes to which
CBF1 is bound, thus converting a repressor into an acti-vert it into a transcriptional activator (Hsieh et al., 1996).
Genetic analysis shows that Dishevelled is antagonistic vator (Zimber-Strobl et al., 1994), possibly in a manner
analogous to Notch bound to CBF1.to Notch. Dishevelled interacts directly with the C-termi-
nus of Notch, and thereby potentially blocks Notch sig- Cytokine Receptors as Oncoproteins
Until recently, members of the cytokine receptor familynaling, thus providing a molecular mechanism for the
inhibitory crosstalk between the Wnt and Notch had not been implicated in oncogenesis. However, the
murine myeloproliferative leukemia virus oncoprotein,pathways.
Homologs of all these components of the Notch sig- v-Mpl, is a mutant form of the newly discovered receptor
for thrombopoietin (TPO), a megakaryocyte growth fac-naling pathway have been identified in vertebrates.
There are at least four Notch family receptors in mam- tor. The TPO receptor (c-Mpl) is a typical member of
the cytokine receptor family, which activates JAK2 andmals, and several ligands, such as Jagged. The DNA-
binding protein RBP-Jk/CBF1/KBF2 (CBF1) is the Su(H) STAT3/STAT5, and is coupled to the ERK MAPK path-
way through Shc (Gurney et al., 1995; Mu et al., 1995).homolog, and the Hes family of bHLH proteins are Hairy/
Enhancer of split homologs. Notch function is also con- v-Mpl has part of the viral Env protein fused to the
C-terminus of the TPO receptor starting just to theserved in vertebrates. A truncated form of Xenopus
Notch lacking the extracellular domain affects cell fate N-terminal side of the transmembrane domain. v-Mpl
retains the extracellular domain cytokine receptordecisions in embryos, and a soluble form of the mouse
Notch intracellular domain blocks MyoD-induced myo- WSXWS motif, and is presumably activated through
constitutive dimerization, thus generating a continuousgenesis. Activated forms of mouse Notch associate with
CBF1, triggering transcriptional activation through the growth signal and blocking differentiation. However, the
exact downstream signals that are required for v-Mpl-CBF1-binding sites in the HES1 promoter (Jarriault et
al., 1995), and Hes1 can block MyoD-induced myogen- mediated transformation are not known; it is not neces-
sarily the case that the JAK/STAT pathway is essential,esis in some systems. A CBF1-independent pathway
may also be involved, however, in Notch-mediated an- since proliferation induced by the erythropoietin (EPO)
receptor does not require STAT activation. Activation oftagonism of MyoD-induced myogenesis (Shawber et al.,
1996). the ERK MAPK pathway and other pathways may be
Review: Oncoprotein Networks
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important in transformation. In this connection, it isnota- example, v-Raf is a retroviral oncoprotein, and Raf1,
which is a MAPKKK, can be oncogenically activated byble that association with and activation of the EPO re-
ceptor at the cell surface by an oncogenic retroviral Env simple addition of a membrane-targeting signal. Dissec-
tion of which of these effectors is required for transfor-protein, gp55, is responsible for leukemictransformation
by Friend leukemia virus (Li et al., 1995b). mation by Ras has been made possible by the use of
activated Ras mutants carrying point mutations at spe-TGFb Receptors
The TGFb receptor and downstream signaling compo- cific sites in the effector domain (White et al., 1995).
These results indicate that multiple cellular pathways,nents are also targets for mutation in cancer. For in-
stance, the gene encoding the TGFb receptor type II is including Raf1, are activated by Ha-Ras and contribute
to Ha-Ras-induced mammalian cell transformation. In-commonly inactivated in colon carcinoma with micro-
satellite instability (Markowitz et al., 1995), and the deed, it has been shown that Ras activation of Raf/
MAPK-independent pathways is sufficient to cause tu-SMAD2 and SMAD4 (DPC4) genes have also been found
inactivated or deleted in colon carcinoma (Eppert et al., morigenic transformation (Khosravi-Far et al., 1996).
Among the targets for Ras required for transformation1996; Hahn et al., 1996b). Certain members of the Smad
family (Smad1, -2, -3,and -5) aredirectly phosphorylated is Rac, a member of the Rho family of small G proteins.
Rac itself has modest transforming activity when Gly12by ligand-activated TGFb family receptors, oligomerize
with Smad4, and are then translocated into the nucleus. is mutated to Val, but it cooperates with activated Raf1
for transformation, and dominant negative Asn17 mutantOnce in the nucleus, Smad protein oligomers act as
transcriptional activator subunits (Liu et al., 1996) and Rac blocks Ras transformation (Khosravi-Far et al.,
1995; Qiu et al., 1995). The Ras-induced pathway leadingmediate TGFb-induced gene expression. For instance,
Xenopus Smad2 interacts with the sequence-specific to Rac activation is not known. Rho is also required for
Ras transformation and G1 progression.DNA binding protein, FAST-1, a member of the winged
helix family of proteins, that binds to an activin-response Rho Family Proteins and the Cytoskeleton
Hints that the cytoskeleton might play a critical role inelement in the Mix.2 gene. Smad2 and Smad4 associate
in response to TGFb, and this interaction is required for transformation have been in evidence for many years.
Transformed cells show altered patterns of expressiongrowth inhibition (Lagna et al., 1996). Mutant Smad2
proteins carrying point mutations found in colon carci- of cytoskeletal proteins; for instance, novel tropomyosin
isoforms are expressed. Transformed cells commonlynomas are no longer phosphorylated or translocated
into the nucleus in response to TGFb (Eppert et al., have disorganized actin cytoskeletons, which may be
tied to the ability of transformed cells to grow in1996). Collectively, these observations provide strong
evidence that TGFb receptor signaling through activa- an anchorage-independent fashion. Normally adherent
cells require integrin engagement to proliferate, and thetion of the Smad pathway plays an important role in
tumor suppression. concentration of ligand-occupied integrins into focal ad-
hesions is a key factor in the anchorage and organization
of actin microfilament bundles into stress fiber arrays.
Ras Family Proteins and Cancer The Rho family of small G proteins, which regulate
Activating mutations in H-Ras, K-Ras and N-Ras have actin-containing structures and plasma membrane to-
all been found in human tumors, and the frequency of pology, has recently assumed increasing importance in
Ras mutations is among the highest for any gene in oncogenesis. Rho causes actin stress fiber formation,
human cancers. Recently, two less well-known Ras-like Rac stimulates membrane ruffling and lammellipodia
genes, TC21 and R-Ras, have become potential targets formation, and Cdc42 induces filopodia formation
for mutational activation in human tumors. TC21 mu- (Nobes and Hall, 1995). A number of potential effector
tated at residues 22 and and 61 (equivalent to Ras 12 proteins have been found to associatepreferentially with
and 61) transforms NIH3T3 cells (Graham et al., 1994), the GTP-bound forms of Rho family proteins. Cdc42 and
and activating mutations in TC21 have been found in Rac bind many proteins in common through a short
human tumors (Huang et al., 1995); R-Ras mutated at recognition sequence (CRIB) with the consensus ISXPX4
residues 38 or 87 can transform NIH3T3 cells, although FXHXXHVG (Burbelo et al., 1995). Among the direct tar-
mutations in R-Ras have not been detected in human gets for Cdc42 and Rac are several protein kinases,
tumors (Cox et al., 1994; Saez et al., 1994). Ras GAPs, including Pak1 and Rho kinase. Activated Rac and
which promote Ras GTPase activity and downregulate Cdc42 stimulate the JNK/SAPK and p38 MAPKs (Coso
Ras signaling, have also been implicated in tumorigene- et al., 1995; Minden et al., 1995), possibly through bind-
sis. Neurofibromin, the product of the NF1 tumor sup- ing of Rac/Cdc42 to Pak1, which leads to its activation
pressor gene that is mutated in type 1 neurofibro- (Bagrodia et al., 1995). Although it is not yet clear pre-
matosis, is a Ras GAP with a central domain related to cisely which targets areessential for different responses
p120GAP. The lack of neurofibromin leads to elevated induced by each family member, the use of specific
basal levels of Ras GTP in NF1-derived schwannomas point mutations in the effector domains of theseproteins
(DeClue et al., 1992), which could play a causal role in has begun to allow a dissection of the different pathways
the etiology of these tumors. that can be activated (Lamarche et al., 1996). Thus, acti-
A number of effectors for Ras proteins have been vation of Pak1 proves not to be required for Rac/Cdc42-
identified, which bind preferentially to Ras in the GTP- induced cytoskeletal changes or G1/S progression. In
bound state. These include Raf1, the p110 PI3 kinase contrast, a Rac mutant unable to interact with the Rho
catalyticsubunit, PKCz, RalGDS, Rin1, and MEKK1. Sev- kinase cannot induce lamellipodia or G1 progression
(Lamarche et al., 1996).eral of these have been implicated in tumorigenesis. For
Cell
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The importance of Rho family small G proteins in MAP Kinase Pathways and Transformation
transformation is emphasized by the large number of The MAP kinase module, which consists of three protein
mutant activated GDP/GTP exchange factors for this kinases in series, a MAPK, a MAPKK, and a MAPKKK,
family that have been found to possess fibroblast trans- has emerged as one of the most important membrane-
forming activity. The first example was Dbl, an oncopro- to-nucleus signaling pathways in eukaryotes. This mod-
tein derived through artifactual truncation that occurred ule is highly conserved and extremely versatile. In yeast,
during transfection. Additional examples include Vav, MAPKs are used for a variety of functions, transmitting
Lbc, Tiam1, Tim, Ost, Ect2, Lsc, and FGD1. The function the response to extracellular stimuli such as phero-
of these multiple exchange factors is not fully under- mones, osmotic stress, and cell wall integrity. In higher
stood, but they all have a core domain containing a eukaryotes, the MAPK module has been adopted to
region of z330 residues known as the Dbl-homology transmit responses from many different types of surface
domain, together with an upstream pleckstrin homology receptor, including receptor PTKs, G protein-coupled
domain, which is required for GDP/GTP exchange (Quil- receptors, cytokine receptors, and possibly even the
liam et al., 1995). The specificities of most of these ex- TGFb receptor family. Activated MAPKs are translo-
change factors remain to be determined, but Dbl and cated into the nucleus. In mammals, a number of nuclear
Vav are pleiotropic exchange factors that can activateall MAPK targets have been identified, including the ternary
three family members, whereas FGD1 can only activate complex factors in the Ets family that stimulate the ex-
Cdc42 (Olson et al., 1996). The ability of FGD1 to trans- pression of the c-fos gene via the SRE. Not surprisingly,
form can be explained by the ability of Cdc42 to activate constitutive activation of MAP kinase-mediated mito-
Rac, which in turn can activate Rho, thus leading to genic signaling pathways elicits transformation.
activation of all three family members. The essential role The three well-characterized MAPK pathways in ver-
in transformation of the Rho family proteins underscores tebrates are the ERK, JNK/SAPK, and p38 pathways.
the critical connection between the cytoskeleton and So far, only the ERK MAPK pathway has been implicated
transformation. in oncogenesis, even though the c-Jun protooncopro-
Other Cytoskeletal Connections tein is activated by JNK/SAPK phosphorylation and is
Merlin/schwannomin, the product of the NF2 tumor sup- required for Ras transformation (Johnson et al., 1996b).
pressor gene, which is mutated in neurofibromatosis
Moreover, the JNK/SAPK and p38 pathways lead to
type 2 patients, is a member of the ezrin/radixin/moesin
the activation of many of the same transcription fac-
(ERM) family (Belliveau et al., 1995). ERM family proteins
tors, such as Elk1 and Sap1a. Perhaps transformation
bind to F-actin and are localized to microvillar cores in
requires phosphorylation of targets unique to ERK
many cell types. The function of these proteins is not
MAPKs, or else the balance of substrate phosphoryla-
fully understood, but they can all interact with the cyto-
tion is critical and is not achieved by p38 or JNK/SAPK.plasmic domain of CD44 (Tsukita et al., 1994), which
Indeed, whereas constitutively activated mutantMEK1s,is a cell surface receptor for hyaluronan. CD44 shows
which activate ERK1/2, elicit transformation of fibro-striking variability in the structure of its extracellular
blasts (Cowley et al., 1994; Mansour et al., 1994), andomain as a result of alternative splicing, and some
activated mutant MEKK1, which activates both JNK/isoforms are strongly correlated with the metastatic
SAPK and p38, results in apoptosis (Johnson et al.,phenotype. Recent evidence suggests that Rho regu-
1996a). A proapoptotic function for JNK/SAPK has alsolates the CD44/ERM interaction and, conversely, that
been noted in PC12 cells, where it is counteracted bythis interaction may regulate Rho activation (Hirao et al.,
activation of ERK (Xia et al., 1995). Transformation of1996). The absence of merlin could therefore affect Rho
fibroblasts by upstream activators of ERK MAPK, suchfunction and play a role in transformation.
as activated Ras and Raf1, is blocked by a dominant
negative mutant of MEK1, establishing that activationPlasma Membrane-to-Nucleus Signaling Pathways
of ERK MAPK is required for transformation (Cowley etOur knowledge of signaling pathways activated by
al., 1994). One critical function for the Ras/ERK MAPKgrowth factor receptor PTKshas been advancing rapidly
pathway could be mitogen-induced cyclin D expression,(Figure 2). A number of SH2/SH3 adaptor proteins play
which is needed for G1 progression (Lavoie et al., 1996).critical roles in transducing signals from activated re-
Ras has other effectors, however, which may play rolesceptor PTKs to downstream signaling pathways. A good
in transformation. Indeed, it should be noted that trans-example is Grb2, which recruits the Ras GDP/GTP ex-
formation by activated MEK1 is blocked by microin-change factor Sos to the plasma membrane upon bind-
jected Ras antibody showing that direct activation ofing to activated receptor PTKs. Adaptors such as Crk,
ERK1 targets is not sufficient for transformation (CowleyNck, and Shc have been implicated in oncogenesis,
et al., 1994); ERK-induced autocrine expression ofeither through their conversion into viral oncoproteins
growth factors that act back on surface receptors that(v-Crk), or else because they transform cells when over-
signal through Ras may be important for transformation.expressed (Nck and Shc). Shc is an intermediary in the
Another oncoprotein connected with the ERK MAPKactivation of Ras and the ERK MAPK pathway. Nck may
pathway is Tpl2, originally identified as the product of anbe connected to the actin cytoskeleton and Rho family
oncogene associated with the progression of Moloneyproteins, since Nck SH3 domains bind known Rac and/
murine leukemia virus-induced T cell lymphomas in rats.or Cdc42 targets, including Pak1. An Nck/Pak1 complex
The same gene was identified as an oncogene in a trans-is translocated to activated growth factor receptor PTKs
fection assay, and called Cot. In both cases, the onco-via the Nck SH2 domain, increasing Pak1 activity (Galis-
protein is C-terminally truncated; while this truncationteo et al., 1996). Pak1 in turn can lead to activation of
the JNK/SAPK and possibly the ERK MAPK pathways. may potentiate transforming activity, however, it is not
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Figure 2. Membrane-to-Nucleus Signaling Pathways Involved in Cancer
Proteins that have been implicated as oncoproteins or tumor suppressor proteins are in white letters on black fill.
needed for transformation. Tpl2/Cot is a protein-serine of PI3,4,5P3 and PI3,4P2 in cells. It is assumed that these
act as second messengers, but identification of theirkinase related to the MAPKKK family, and has been
shown to phosphorylate and activate MEK1 (and JNKK) effector proteins has proved difficult. Recently, how-
ever, c-Akt, which was originally identified as a protoon-in vitro and to activate ERK1 (and JNK/SAPK) in vivo
(Salmeron et al., 1996). ERK MAPK activation induced coprotein, has emerged as a prime candidate. c-Akt is
a protein-serine kinase with an N-terminal pleckstrinby the Tpl2 protein is blocked by dominant negative
mutants of Ras and Raf-1, and a kinase-deficient Tpl2 homology (PH) domain, which, like other PH domains,
binds to phosphoinositides. In vivo, c-Akt is activatedmutant downregulates mitogenic signals induced by
v-Ha-Ras or v-Raf, suggesting that Tpl2 interacts with by stimuli that activate PI3K, as well as by mutationally
activated forms of the p110 PI3K catalytic subunit, andthe ERK MAPK cascade (Patriotis et al., 1994). The fact
that three oncoproteins, Raf, Mos, and Tpl2, are direct is blocked by inhibitors of PI3K activity. Mutation of
a conserved residue in the PH domain blocks c-Aktactivators of MEK1 underlines the importance of the
ERK MAPK pathway in transformation. activation (Franke et al., 1995). c-Akt activation in vivo
requires phosphorylation of two residues, one in thePI3 Kinase and Transformation
The PI3 kinase (PI3K) pathway is another receptor-acti- activation loop and one in the C-terminal tail. In vitro,
c-Akt activity has been reported to be stimulated prefer-vated pathway implicated in oncogenesis. PI3K activity
is stimulated by many types of extracellular signal, es- entially butweakly by PI3,4P2 (Franke et al., 1995; Klippel
et al., 1997), although in other studies no stimulationpecially those involving activation of receptor PTKs.
Through the use of receptor PTK mutants that fail to was observed (James et al., 1996). The extent of phos-
phoinositide activation is significantly less than ob-activate PI3K and PI3K inhibitors, such as wortmannin, a
role for PI3K has been delineated in a number of cellular served in vivo, suggesting that phosphorylation of the
activating sites in c-Akt plays an important role in itsresponses, including 70K S6 kinase activation, ruffling,
and chemotaxis. PI3K first came into view as an activity activation in vivo (Kohn et al., 1996). v-Akt, theoncogene
product of the AKT8 murine retrovirus, is a Gag-Aktassociated with middle T antigen, the transforming pro-
tein of polyoma virus, implicating it in transformation. fusion protein, in which Gag is joined to the PH domain.
Unlike c-Akt, v-Akt is myristoylated, and constitutivelySubsequent work showed that binding of PI3K to MT
antigen, via P.Tyr315, which is phosphorylated by the membrane-associated and activated. Thus, a plausible
mechanism of Akt activation in the cell involves induc-MT-associated c-Src PTK, is crucial for transformation.
The importance of PI3K in transformation has been un- ible binding of Akt to PI3,4P2 in the plasma membrane,
where the translocated protein is activated throughderscored by the recent identification of a new avian
sarcomavirus, ASV16, whose oncogene encodes a Gag- trans- or autophosphorylation, which may be facilitated
through PH domain-mediated dimerization. ConsistentPI3K p110a catalytic subunit fusion oncoprotein, Gag-
P3K, which has PI3K activity. with this, membrane-anchored forms of Akt are acti-
vated regardless of whether the PH domain is presentPI3K generates 39 phosphoinositides, PI3,4,5P3, PI3,
4P2, and PI3P, and PI3K activation increases the levels (Kohn et al., 1996). However, even if the major role of
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PI3,4P2 in c-Akt activation is to recruit the protein to the chromosomal translocation in a small subset of acute
promyelocytic leukemias (Chen et al., 1993), repressesmembrane, it may still act as a true second messenger
with other effectors. expression of a cyclin A promoter reporter gene. One
of the two possible PLZF-RARa fusion proteins containsThe critical targets for Akt phosphorylation are not
known, but it has been shown that Akt can phosphory- the RARa transactivation domains and the PLZF DNA-
binding domain, and this may allow it to transactivatelate and inhibit GSK3 in response to insulin, providing
an intriguing connection to the Wnt pathway (Cross et rather than repress cyclin A expression, which is essen-
tial for cell cycle progression and growth. CHOP, whichal., 1995). Akt may also be upstream of the 70K S6
kinase, which can phosphorylate and inhibit GSK3 as was fingered as an oncoprotein through its identification
as a chromosomal translocation fusion partner of thewell. Finally, recent evidence suggests that activated
Akt plays a role in protection from apoptosis, which Ews RNA-binding protein in a myxoid liposarcoma, is a
member of the C/EBP family of basic-leucine zippercould also be important for its transforming activity.
Other membrane-to-nucleus signaling pathways are transcription factors. CHOP can act as an antagonist
of C/EBP-induced transcription, and block C/EBP-involved in transformation. For instance, at least two
components of the NF-kB system have been identified induced differentiation of adipocytes (Batchvarova et
al., 1995). Transformation of fibroblasts requires a con-as oncoproteins, i.e., Rel and Bcl3. As indicated above,
the Notch and Wnt receptor signal pathways also play tribution from the Ews fusion partner, but CHOP may
act as an oncoprotein by preventing C/EBP-inducedroles in oncogenesis. However, another well-character-
ized membrane-to-nucleus signaling system, the JAK/ expression of differentiation genes.
It is also clear that coactivator proteins, which do notSTAT pathway, has to date not been implicated in carci-
nogenesis; indeed, proliferative signaling via cytokine bind directly to DNA, are potential targets for oncopro-
teins, as evidenced by the fact that adenovirus E1Areceptors, such as the EPO receptor, does not require
activation of JAK/STAT. Nevertheless, certain activated binds to the CBP and p300 coactivators, resulting in
inactivation of certain CBP/p300 transcription stimula-mutants of Hopscotch, the Drosophila JAK homolog,
cause a leukemia-like phenotype owing to overprolifera- tory functions (Arany et al., 1995). Another example of
an oncoprotein that does not bind directly to DNA istion of blood cells, which requires Drosophila STAT (Yan
et al., 1996). It would be interesting to look for similar Bmi1, which is a chromatin structural protein related to
the Polycomb family of Drosophila repressors that isactivating mutants in human leukemias.
upregulated by proviral integration in MuLV-induced
thymomas (van Lohuizen et al., 1991). Such proteinsNuclear Proteins and Cancer
The number of oncogenic proteins that act in thenucleus appear to regulate and switch off large blocks of chro-
matin. Bmi1 may act by blocking expression of geneshas continued to rise steadily. These include novel tran-
scription factors, chromatin regulatory proteins, and a required for lymphoid differentiation.
Pml, which was uncovered as a translocation partnervariety of transcriptional regulators. Many of these have
been identified as the products of fusion genes gener- of RARa in promyelocytic leukemia (PML), is a compo-
nent of a novel nuclear structure, called PODS, whoseated by chromosomal translocations in leukemias. Sev-
eral oncogenes encode transcriptional activators, and function is still somewhat enigmatic (Dyck et al., 1994;
Koken et al., 1994). In cultured cells, expression of thethey will not be reviewed here. It should be noted, how-
ever, that the thorny issue of the critical target genes Pml-RARa protein disrupts PODS in a retinoic acid re-
versible fashion; since PML is reverted by retinoic treat-that need to be induced by such oncoproteins is still
unresolved. In this connection, v-Jun appears to have ment of patients, the oncogenic activity of Pml-RARa
action is likely to involve disorganization of PODS. Con-attenuated transcriptional activation function compared
to c-Jun (Gao et al., 1996), and this may be true for other versely, Pml, through its PODS organizing activity, acts
as a growth suppressor. PODS are also disrupted byoncoproteins that are transcriptional activators.
A building theme is the function of oncoproteins as adenovirus E4-ORF3, which is required for viral replica-
tion (Doucas et al., 1996), implying that PODS play atranscriptional repressors. The first example was v-ErbA,
which is a repressor of thyroxine receptor (c-ErbA) in- role in DNA replication.
The VHL gene is mutated in the hereditary cancerduced erythroid differentiation genes. WT1, the product
of the Wilms’ tumor suppressor gene, has also been syndrome, von Hippel Lindau disease, which predis-
poses to renal carcinoma and pheochromocytoma. VHLshown to be a repressor of certain genes, antagonizing
the Egr family of transcriptional activators. Another re- proves to be an alternative A type subunit of the RNA
polymerase II cofactor Elongin (SIII), which stimulatescent example is v-Qin, the oncogene product of ASV31,
which acts as a repressor and is a member of the HNF- transcription elongation by RNA polymerase II in vitro,
and is assumed to ensure complete gene transcription3/forkhead family of transcriptional factors (Li et al.,
1995a). Evi1, whose expression is activated in murine (Duan et al., 1995; Kibel et al., 1995). Elongin is a hetero-
trimer consisting of a transcriptionally active A subunitmyeloid leukemias by retroviral insertions and in human
acute myelogenous leukemia by chromosomal translo- together with B and C regulatory subunits. Replacement
of the normal Elongin A subunit with VHL inhibits it elon-cations and inversions, interferes with myeloid differen-
tiation and is also a repressor (Lopingco and Perkins, gation activity (Duan et al., 1995). Presumably, this regu-
lates the levels of particular transcripts that are subject1996).
The promyelocytic leukemia Kruppel-like zinc finger to transcriptional pausing. The absence of VHL activity
could allow the overexpression of specific proteins, in-(PLZF) protein, which is fused to the retinoic acid recep-
tor a (RARa) protein as a result of a variant t(11;17) cluding positive growth regulators. Intriguingly, the ELL
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gene, which is frequently fused to the trithorax-like MLL has been found in eIF-4E-overexpressing NTH 3T3 cells,
although the mechanisms of upregulation appear to dif-gene on chromosome 11 as a result of t(11;19) transloca-
tions in acute myeloid leukemias, encodes a distinct fer. Both ODC and cyclin D1 are implicated in G1 pro-
gression, and it is interesting to note that eIF-4ErequiresRNA polymerase II elongation factor, providing another
connection between the regulation of transcription elon- Ras function and, like Ras, cooperates with v-Myc in
transformation. Finally, overexpression of elongationgation and cell growth (Shilatifard et al., 1996).
Brca1 and Brca2 are huge proteins whose disruption factor EF-1a increases sensitivity to transformation, and
an N-terminally truncated form of EF-1a is implicatedis the underlying cause of a large fraction of hereditary
breast and ovarian cancer. The subcellular localization as an oncoprotein in prostatic cancer.
of Brca1 has been hotly debated, but current opinion
favors a nuclear localization. Brca1 is essential for early
The Cell Cycle and Cancermouse development, which gives little clue to its func-
Direct connections between the cell cycle and cancertion, although it may govern expression of cell cycle
have been evident for some time (Sherr, 1996). Afterregulators. Brca1 has not been shown to have DNA-
some initial uncertainty, it is now clear that the p16 Cdkbinding activity, but the C-terminal335 residues of Brca1
inhibitor gene is a major target for mutational inactiva-have transactivation function whenfused toa DNA-bind-
tion in human cancers. In addition, specific mutationsing domain (Chapman and Verma, 1996). This transacti-
in p16 are the underlying cause of one type of hereditaryvation activity is abolished by point mutations in this
melanoblastoma. Surprisingly, there is no evidence thatregion, which occur naturally in affected individuals,
the three other members of the p16 Cdk inhibitor family,supporting the idea that Brca1 transactivating activity
p15, p18, and p19, are mutated in human cancer. Anis physiologically relevant.
emerging paradigm, however, is that one component ofFinally, the Dek-Can and Set-Can fusion proteins aris-
the p16-cyclin D/Cdk4-Rb axis is mutationally inacti-ing from leukemia-associated translocations found in
vated in most cancer cells (Sherr, 1996). Thus, a tumorleukemia contain the C-terminal domains of Can, which
may have mutations that lead to loss of p16 or Rb, orcontains repeats found in nucleoporins. The Can protein
upregulation of cyclin D expression, or a mutation thatis localized to the nuclear and cytoplasmic faces of the
renders Cdk4 insensitive to p16. The net result is thatnuclear envelope, whereas the Can fusion proteins are
Rb and Rb family members areconstitutively inactivatedfound exclusively in the nucleus (Fornerod et al., 1995).
in such cells, providing a trigger for progression fromPotentially, this altered distribution perturbs nuclear im-
G1 into S phase. The best evidence is that cyclin D isport or export of proteins or RNAs.
not required for cell cycle progression in cells bearing
a mutation in one component of this axis, and that p16
fails to block the growth of such cells.Protein Synthesis and Oncogenesis
An increase in the rate of protein synthesis initiation The other key component in the G1-to-S transition is
cyclin E, which acts in conjunction with Cdk2. Cyclin Ecan also lead to transformation. Two different initiation
factors have been implicated. Overexpression of eIF-4E, is overexpressed in some cancer cells, although the
mechanism has not been established (Keyomarsi andthe mRNA cap-binding subunit of the eIF-4F initiation
factor, elicits fibroblast transformation (Lazaris-Kar- Pardee, 1993). Mutations or deletions that eliminate a
C-terminal Cdk phosphorylation site enhance cyclin Eatzas et al., 1990; Smith et al., 1990). The second initia-
tion factor, eIF-2, is a heterotrimer that forms a ternary function by blocking ubiquitin-mediated degradation,
thus leading to its accumulation. It is possible that muta-complex with GTP and Met-tRNAi, and is needed to
deliver Met-tRNAi to the initiation complex. eIF-2 is neg- tions of this type will be found in cancers. So far, none
of the members of the p21 family of Cdk inhibitors, whichatively regulated through phosphorylation of Ser-51 in
the a subunit; this blocks the action of the eIF-2 GDP- have a broader inhibitory specificity than the p16 family,
has been implicated in tumorigenesis, despite an exten-GTP exchange factor, which is needed to reactivate
eIF-2 after its cargo is delivered. Phosphorylation of eIF- sive search for mutations in the genes for p21, p27,
and p57. It has recently been shown, however, that the2a plays a major role in negative regulation of initiation
of protein synthesis; two protein kinases are known that adenovirus E1A and human papilloma virus E7 trans-
forming proteins have the ability to counteract the Cdkphosphorylate eIF-2a at Ser-51, namely the double-
stranded RNA dependent protein kinase (PKR) and a inhibitory activity of p27 (Mal et al., 1996). This property
of E1A may be important in its ability to override TGFb-heme-regulated protein kinase. Expression of a kinase-
inactive mutant form of PKR causes fibroblast transfor- induced growth inhibition and trigger the growth of qui-
escent cells, which have high levels of p27.mation (Koromilas et al., 1992; Meurs et al., 1993) as a
result of a decrease in eIF-2a phosphorylation. Consis- New players in the regulation of the cell cycle are
continually being uncovered, but none with a clear cuttent with a role for eIF-2a phosphorylation in transforma-
tion mediated by kinase-inactive PKR, overexpression involvement in oncogenesis has been discovered re-
cently. However, an intriguing connection has emergedof an Ala-51 mutant eIF-2a also causes transformation.
Presumably, the general increase in protein synthesis between an old friend, Cdc25, and transformation.
Cdc25A and Cdc25B, but not Cdc25C, can cooperateinitiation capacity results in increased translation of
poorly translated mRNAs encoding specific proteins with activated Ras to transform primary rodent fibro-
blasts (Galaktionov et al., 1995b). Cdc25s are dual-spec-that are important for growth and cell cycle progression.
Indeed, enhanced expression of several proteins, in- ificity phosphatases that dephosphorylate the negative
regulatory phosphates at Thr-14 and Tyr-15 in Cdks,cluding cyclin D1 and ornithine decarboxylase (ODC),
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leading to their activation. Cdc25C activates cyclin with Raf1 and localizes Raf1 to mitochondrial mem-
branes (Wang et al., 1996). Moreover, mitochondriallyB/Cdc2 at the G2/M transition, but the cyclin/Cdk tar-
get(s) for Cdc25A and Cdc25B has not been unequivo- localized Raf1 protects IL3-dependent cells from apop-
tosis induced by IL3 withdrawal, whereas a kinase-inac-cally established. There is reasonable evidence, how-
ever, that Cdc25A acts on Cdk2 complexes, and that tive form of Raf1 potentiates killing. Bcl2 has also been
found to associate with R-Ras (Fernandez-Sarabia andCdc25A activity is required for the G1/S transition. It is
possible that cyclin D-Cdk4 complexes may also be Bischoff, 1993), which could play a role in Raf1 activa-
tion. One potential target for Bcl2-associated Raf1 isCdc25 targets. The exact connection between Cdc25A
and Ras is not clear, but it has been suggested that Ras- Bad itself. A recent clue to the function of Bcl2 family
proteins comes from the finding that their structure isactivated Raf might directly regulate Cdc25A activity
through phosphorylation (Galaktionov et al., 1995a). related to the diphtheria toxin channel (Muchmore et al.,
1996), and that they can act as ion channels in vitro.Another intriguing connection between Cdc25A and
-B and the cell cycle is that the expression of bothCdc25 Channels with distinct properties may be formed by
different combinations of Bcl2 family members. Thisgenes is increased at the transcriptional level by c-Myc
leading to accumulation of Cdc25 protein (Galaktionov system is also a target for viral intervention; for instance,
adenovirus E1B 19K binds to Bax, thus inactivating itet al., 1996). Both Cdc25 genes contain c-Myc/Max-
binding sites in the first intron, which respond transcrip- (Han et al., 1996).
Another important apoptotic regulator is p53, whichtionally to increased c-Myc expression. Moreover, ex-
pression of c-Myc leads to activation of cyclin E-Cdk2 is activated by DNA damage; activated p53 induces or
represses the expression of a number of target genesand cyclin D-Cdk4 complexes in quiescent cells (Steiner
et al., 1995). Further evidence that Cdc25A is an impor- (Levine, 1997 [this issue of Cell]). Among these is the
p21 Cdk inhibitor p21, which acts on cyclin-Cdk4/6 andtant target for c-Myc is that depletion of Cdc25A by
antisense RNA expression or antisense-oligonucleotide cyclin-Cdk2 complexes, playing a role in the arrest of
cells in G1. Activation of p53 is also required for thetreatment blocks c-Myc-induced apoptosis. Consistent
with a role for Cdc25A/B in carcinogenesis, Cdc25A/B induction of apoptosis in response to some but not all
signals. The finding that c-Myc induces apoptosis in theRNA and protein are found to be overexpressed in a
variety of tumors, including breast carcinomas (Galakti- absence of growth factors has been another key finding.
c-Myc is a double-edged sword, being capable of driv-onov et al., 1995b). Moreover, adenovirus E1A increases
Cdc25A activity and expression in quiescent cells, and ing a cell through the cell cycle under appropriate condi-
tions or provoking cell death under suboptimal condi-Cdc25A is required for adenovirus to induce DNA syn-
thesis (Spitkovsky et al., 1996). Cdc25A and Cdc25B are tions. Signals from the IGF1 receptor PTK counteract
the c-Myc-induced apoptotic pathway at many levels,also targets for TGFb, being downregulated at the RNA
and protein level following TGFb treatment. and this allows c-Myc to express its proliferative poten-
tial and explains the requirement for IGF1 for growth of
most cultured cells (Harrington et al., 1994).Apoptosis
An emerging theme in carcinogenesis is the acquired Adherent endothelial and epithelial cells require inte-
grin engagement for survival, and in the absence ofability of tumor cells to avoid undergoing apoptosis in
response to DNA damage or other conditions that would attachment to a substratum undergo apoptosis (Mere-
dith et al.,1993; Boudreau et al., 1995). One of the conse-induce a normal cell to commit suicide. Our understand-
ing of the mechanisms underlying programmed cell quences of the accumulated mutations in a carcinoma
may be to provide a signal that mimics integrin occu-death, or apoptosis, has grown explosively in the past
few years. Signal transduction pathways leading from pancy. This will have the net effect of providing a signal
that permits cells to grow in the absence of anchor-receptors, such as Fas and the TNF receptor, to the
activation of effectors of cell death, such as the Caspase age, and at the same time interdicts the normal apop-
totic response to lack of integrin engagement. Interest-protease family, have been elucidated (Nagata, 1997
[this issue of Cell]). Bcl2 family proteins are key regula- ingly, activated R-Ras increases integrin ligand affinity,
whereas dominant negative mutant R-Ras reduces celltors of this pathway. These proteins hetero- and homo-
dimerize, and have been categorized as either pro- adhesiveness (Zhang et al., 1996).
apoptotic (e.g. Bax or Bad) or anti-apoptotic (e.g. Bcl2 or
Bcl-XL). Thus, the balance of pro- versus anti-apoptotic
ConclusionsBcl2 family members in cells dictates cellular response.
One striking conclusion is that oncogenesis is intimatelybcl2 was identified at the breakpoint of a t(14;18) tran-
connected with a failure of incipient tumor cells to differ-scription in acute lymphocytic B cell leukemia. Expres-
entiate. This can be the consequence of mutations insion of a bcl2 transgene results in the expansion of the B
highly conserved genes that regulate cell fate decisionscell population due to a failure of these cells to undergo
and differentiation, such as Notch and Patched. In addi-normal programmed cell death and elimination.
tion, a number of oncogenic transcription factors act asBoth Bad and Bcl2 have recently been found to be
repressors to block transcription of genes required forregulated through phosphorylation. Bad is phosphory-
differentiation. The importance of constitutively acti-lated at Ser-112/136 in response to IL3 treatment of
vated mitogenic signaling pathways in oncogenesis hascells that require IL3 for survival, and this results in
become increasingly obvious. Activated forms of several14–3–3 binding (Zha et al., 1996). Mutation of Ser-112/
components of the ERK MAP kinase pathway are onco-136 increases the potency of Bad, implying that phos-
phorylation attenuates its killing activity. Bcl2 associates proteins, but new mitogenic signaling pathways, such as
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